Allergan must pay as a result of hundreds of lawsuits alleging it deceptively marketed an opioid acquired from Pfizer, Reuters reports. In the suit, which was filed in federal court in Cleveland, Ohio, Allergan said that the “primary basis” for the claims against it was the alleged improper marketing and sale of Kadian, a form of morphine, in the years before it acquired the rights to the drug a decade ago, the report says. “But now that more than a thousand lawsuits seek to impose liability for that very marketing and sale, Pfizer has rejected any responsibility to indemnify Allergan,” claims Allergan Finance LLC, the subsidiary that filed the lawsuit
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.